FineMark National Bank & Trust lessened its stake in shares of CVS Health Corp (NYSE:CVS) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,589 shares of the pharmacy operator’s stock after selling 1,936 shares during the quarter. FineMark National Bank & Trust’s holdings in CVS Health were worth $1,275,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in CVS. Vanguard Group Inc. boosted its stake in shares of CVS Health by 1.4% in the second quarter. Vanguard Group Inc. now owns 76,557,597 shares of the pharmacy operator’s stock valued at $6,159,825,000 after purchasing an additional 1,056,265 shares during the period. FMR LLC boosted its stake in shares of CVS Health by 22.0% in the second quarter. FMR LLC now owns 30,150,634 shares of the pharmacy operator’s stock valued at $2,425,920,000 after purchasing an additional 5,446,930 shares during the period. Northern Trust Corp boosted its stake in shares of CVS Health by 5.5% in the second quarter. Northern Trust Corp now owns 15,618,081 shares of the pharmacy operator’s stock valued at $1,256,631,000 after purchasing an additional 807,639 shares during the period. Nordea Investment Management AB boosted its stake in shares of CVS Health by 8.4% in the second quarter. Nordea Investment Management AB now owns 14,154,922 shares of the pharmacy operator’s stock valued at $1,138,905,000 after purchasing an additional 1,100,373 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of CVS Health by 4.1% in the third quarter. Dimensional Fund Advisors LP now owns 10,856,659 shares of the pharmacy operator’s stock valued at $882,860,000 after purchasing an additional 430,377 shares during the period. 83.11% of the stock is owned by institutional investors.
A number of research analysts recently issued reports on CVS shares. Raymond James Financial upgraded shares of CVS Health from an “outperform” rating to a “strong-buy” rating and set a $90.00 price target for the company in a research note on Thursday, January 4th. They noted that the move was a valuation call. Citigroup set a $76.00 price target on shares of CVS Health and gave the stock a “hold” rating in a research note on Monday, December 4th. Jefferies Group set a $76.00 price target on shares of CVS Health and gave the stock a “hold” rating in a research note on Monday, December 4th. Leerink Swann set a $85.00 price target on shares of CVS Health and gave the stock a “buy” rating in a research note on Monday, December 4th. Finally, Needham & Company LLC lifted their price target on shares of CVS Health from $79.00 to $85.00 and gave the stock a “buy” rating in a research note on Monday, December 4th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $87.03.
Shares of CVS Health Corp (NYSE CVS) opened at $69.27 on Friday. The company has a current ratio of 1.02, a quick ratio of 0.52 and a debt-to-equity ratio of 0.59. CVS Health Corp has a 1-year low of $66.45 and a 1-year high of $84.00. The firm has a market cap of $70,276.63, a P/E ratio of 10.71, a price-to-earnings-growth ratio of 1.15 and a beta of 1.03.
CVS Health (NYSE:CVS) last released its quarterly earnings data on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.04. CVS Health had a net margin of 3.58% and a return on equity of 17.21%. The company had revenue of $48.39 billion for the quarter, compared to analysts’ expectations of $47.54 billion. During the same quarter last year, the company earned $1.71 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. sell-side analysts expect that CVS Health Corp will post 6.37 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3255004/cvs-health-corp-cvs-shares-sold-by-finemark-national-bank-trust.html.
CVS Health Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.